Pharmaceutical Mixer Control Using Biomarker-Based Phenotypes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing health-related data management systems fail to adaptively provide personalized medical prescriptions based on user phenotypes, limiting the effectiveness of digital treatments.
Innovation Solution
A method and apparatus that determine a user's phenotype based on biomarkers, enabling adaptive digital treatment algorithms and controlling pharmaceutical mixers to provide personalized treatment based on the user's phenotype.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If health-related data is collected through wearable devices, then data availability is improved, but the ability to provide adaptive personalized treatment is insufficient
Solution Approach 1:
The system changes parameters by determining user phenotypes based on biomarker data and using these phenotype classifications to dynamically adjust treatment parameters. The processor analyzes health data to identify phenotype categories (e.g., metabolic phenotypes, cardiovascular phenotypes) and modifies treatment protocols accordingly, transforming static data collection into adaptive treatment delivery.
2Ease of manufacture
If generic treatment protocols are used, then ease of implementation is improved, but treatment effectiveness for individual users is reduced
Solution Approach 1:
The system applies local quality by providing customized treatment parameters tailored to each user's specific phenotype category. Instead of uniform treatment protocols, the processor generates phenotype-specific treatment recommendations that address individual metabolic, cardiovascular, or other health characteristics, ensuring treatment effectiveness is optimized for each user's unique biological profile.
3Adaptability or versatility
If phenotype-based adaptive treatment is implemented, then treatment personalization is improved, but system complexity increases
Solution Approach 1:
The system reduces complexity through segmentation by dividing the continuous spectrum of health data into discrete phenotype categories. The processor classifies users into specific phenotype groups (e.g., insulin-resistant phenotype, inflammatory phenotype) based on biomarker patterns, allowing complex adaptive treatment to be managed through standardized category-based protocols rather than continuous customization.
Data Source
AI summary
A method for controlling a pharmaceutical mixer based on a phenotype of a user and an apparatus for performing the method. In the method, one or more memory devices store instructions operable when executed by a processor to perform the steps: receiving data related to a biomarker of a user; determining a phenotype of the user based on the biomarker; automatically transmitting a control signal to the pharmaceutical mixer based on the determined phenotype of the user; and performing digital treatment based on the phenotype.